N4 Pharma

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated

E_DEPRECATED Error in file �functions_general.php� at line 326: Function utf8_encode() is deprecated N4 Pharma logo

E_DEPRECATED Error in file �functions_general.php� at line 186: Function utf8_encode() is deprecated

N4 Pharma was formed in 2014 by Nigel Theobald, the former Chief Executive of AIM quoted Oxford Pharmascience Group plc. It is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma’s reformulation work falls under two divisions:

generic, already commercialised, drugs; and
delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma’s most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma’s reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma’s business model is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma’s revenues should be derived from up front milestone and royalty payments associated with the licence.

Keywords:

Company Profile

N4 Pharma